NuPathe (PATH) Receives Additional Notice of Allowance for Zecuity Patent

January 2, 2013 8:33 AM EST
Get Alerts PATH Hot Sheet
Trade PATH Now!
Join SI Premium – FREE
NuPathe Inc. (Nasdaq: PATH) announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for U.S. Patent application 12/214,555 titled "Polyamine Enhanced Formulations for Triptan Compound Iontophoresis." This application relates to methods of treating a migraine by administering a triptan using an iontophoretic patch that contains NuPathe's proprietary hydrogel polyamine formulation. Given this action, NuPathe expects the patent to issue within the next few months. Once issued, the patent will provide additional patent protection for Zecuity", NuPathe's lead product candidate for the treatment of migraine.

This coverage is in addition to that provided by NuPathe's two U.S. patents, Patent No. 7,973,058 titled "Transdermal Methods and Systems for Delivery of Anti-Migraine Compounds" and Patent No. 8,155,737 titled "Pharmacokinetics of Iontophoretic Sumatriptan Administration," both of which expire in April 2027. Upon approval of NuPathe's New Drug Application (NDA) for Zecuity, NuPathe expects to list each of these patents in the U.S. Food & Drug Administration's (FDA) Orange Book. NuPathe also has additional patent applications pending in the U.S. and other territories for its migraine patch.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, FDA, Litigation

Add Your Comment